ABSTRACT
Background: The cytostatic effects of the polyphenol curcumin and Viscum album extract (VAE) were assessed in soft-tissue sarcoma (STS) cells. Methods: Eight human STS cell lines were used: fibrosarcoma (HT1080), liposarcoma (SW872, T778, MLS-402), synovial sarcoma (SW982, SYO1, 1273), and malignant fibrous histiocytoma (U2197). Primary human fibroblasts served as control cells. Cell proliferation, viability, and cell index (CI) were analyzed by BrdU assay, MTT assay, and real-time cell analysis (RTCA). Results: As indicated by BrdU and MTT, curcumin significantly decreased the cell proliferation of five cell lines (HT1080, SW872, SYO1, 1273, and U2197) and the viability of two cell lines (SW872 and SW982). VAE led to significant decreases of proliferation in eight cell lines (HT1080, SW872, T778, MLS-402, SW982, SYO1, 1293, and U2197) and reduced viability in seven STS lines (HT1080, SW872, T778, MLS-402, SW982, SYO1, and 1273). As indicated by RTCA for 160 h, curcumin decreased the CI of all synovial sarcoma cell lines as well as T778 and HT1080. VAE diminished the CI in most of the synovial sarcoma (SW982, SYO1) and liposarcoma (SW872, T778) cell lines as well as HT1080. Primary fibroblasts were not affected adversely by the two compounds in RTCA. Conclusion: Curcumin and VAE can inhibit the proliferation and viability of STS cells.
Funding
This work was supported by the FoRUM grant (K090-15) of the Ruhr-University Bochum, Germany.
Competing interests
The authors declare that they have no potential conflicts of interest.
Authors' contributions
KH designed the study, analyzed the data, and drafted the manuscript. BB, AD, and TH helped to draft the manuscript and participated in the design of the study. FJ analyzed the data and coordinated the experiments. MR contributed to cell lines. AH performed the statistical analysis. CW participated in the design of the study. ML conceived the study and participated in its design and coordination. MB performed the experiments, analyzed the data, and drafted the manuscript.